Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 19:2:134-6.
doi: 10.1016/j.mmcr.2013.06.003.

Therapeutic drug monitoring in voriconazole-associated hyponatremia

Ren-Ai Xu  1 , Shuang-Li Zheng  2 , Li-Li Xiao  2 , Xue-Ding Cai  2 , Xi-Xi Lai  2 , Guan-Yang Lin  3 , Lu-Feng Hu  3 , Chun-Hong Zhang  3 , Zhi-Sheng Xu  3 , Xiu-Hua Zhang  2
Affiliations

Therapeutic drug monitoring in voriconazole-associated hyponatremia

Ren-Ai Xu et al. Med Mycol Case Rep. .

Abstract

Voriconazole is a second generation triazole antifungal agent and the first choice therapy for invasive aspergillosis (IA). Although voriconazole may be associated with many adverse events, hyponatremia has been rarely reported which potentially could result in death. Therapeutic drug monitoring (TDM) and individualization of therapy by measuring voriconazole plasma concentrations improved the efficacy and safety in patients. We report the effect of TDM to adjust voriconazole dosage in a voriconazole-related hyponatremia patient.

Keywords: Hyponatremia; Invasive pulmonary aspergillosis; Therapeutic drug monitoring; Voriconazole.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Day+52 after voriconazole treatment the lung lesions are no longer visible, and lung CT shows only minor abnormalities compared to before (left: before treatment, right: after treatment).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ader F. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: an emerging fungal disease. Current Infectious Disease Reports. 2010;12(6):409–416. - PubMed
    1. Walsh T.J., Anaissie E.J., Denning D.W. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases. 2008;46(3):327–360. - PubMed
    1. Isobe K., Muraoka S., Sugino K. [Case of pulmonary aspergillosis associated with inappropriate antidiuretic hormone syndrome caused by voriconazole therapy] Nihon Kokyūki Gakkai zasshi. 2007;45(6):489–493. - PubMed
    1. Teranishi J., Nagatoya K., Kakita T. Voriconazole-associated salt-losing nephropathy. Clinical and Experimental Nephrology. 2010;14(4):377–380. - PubMed
    1. Kim K.H., Lee S., Yun N.R. Voriconazole-associated severe hyponatremia. Medical Mycology. 2012;50(1):103–105. - PubMed

LinkOut - more resources